RxDoctor Payments Data

Jessica Wright, NP

Primary Care · Montgomery, INNPI 1205351830

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 28.0% of the total. 2025 is the largest year on record at $345, 3.1 times the $112 reported in 2021.

$691in general payments, 2019–2025

Across 42 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$193
  • Lilly USA, LLC$118
  • Takeda Pharmaceuticals U.S.A., Inc.$110
  • Tris Pharma Inc$64
  • Novo Nordisk$51
  • AstraZeneca$45
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$691 in reported general payments places this provider in the 70th percentile of 113 primary care providers in Indiana.

See all primary care providers in Indiana

Medicare billing

Part B allowed, 2024
$31,226
Medicare patients
94
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$52,636
MounjaroTirzepatide23$22,365
Candesartan Cilexetil12$669
Atorvastatin Calcium79$656
Levothyroxine Sodium51$539
Nebivolol Hcl11$463
Metoprolol Succinate32$428
Rosuvastatin Calcium59$394
Losartan Potassium79$348
Tamsulosin Hcl20$337
Bumetanide14$283
Gabapentin28$267
Pantoprazole Sodium13$264
Lansoprazole15$230
Citalopram HbrCitalopram Hydrobromide72$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$52,63639 claims
Lilly USA, LLCMounjaro$118$22,36523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 113 primary care providers in Indiana.

Other primary care in Montgomery

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →